Skip to content

Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection

Possible Neuroprotective Effects of Ketamine in Children With Severe Traumatic Brain Injury

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00556387
Enrollment
0
Registered
2007-11-12
Start date
2008-12-31
Completion date
2012-12-31
Last updated
2013-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Brain Injury

Keywords

traumatic brain injury

Brief summary

The purpose of this study is to determine the possible effects of an anesthetic agent called Ketamine on the injured brain in children. The researchers think that it will effect the outcomes of children with these injuries.

Interventions

DRUGsaline

1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)

DRUGKetamine

1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)

Sponsors

University of Arkansas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
1 Months to 16 Years
Healthy volunteers
No

Inclusion criteria

* are 1 month to 16 years of age; AND * are admitted to the PICU following severe TBI (any GCS 3-8 inclusive) within 8 hours after the injury; AND * are intubated and ventilated for the management of TBI; AND * are anticipated to have an indwelling arterial or venous catheter for blood sampling during the first three days of study enrollment; AND * have an intra-cranial pressure (ICP) monitoring device for management of TBI.

Exclusion criteria

* are less than 4 kilograms in weight upon admission * are less than 1 month of age; * are greater than 16 years of age; * have a clinical diagnosis of non-accidental TBI; * have suffered immersion injury or prolonged hypoxic injury (lasting greater than 10 minutes); * have a known allergy to ketamine; * have a planned removal of endotracheal tube or the removal of central venous catheter AND arterial catheter within 72 hours of study enrollment; * have a current history of neuromuscular disease; * have a current history of hepatic failure; * have a current history of glaucoma * require chronic treatment with anti-epileptic drugs (AEDs) or devices; * more than 8 hours have elapsed from the time of injury to PICU admission; * have documentation of a positive pregnancy test at the time of enrollment; * if there is a lack of commitment to aggressive intensive care therapies (the subject is either on a DNR status due to pre-existing medical condition, or the family decides to withdraw support prior to participation in the study due to other multiple severe injuries and organ failures resulting from the trauma).

Design outcomes

Primary

MeasureTime frame
To compare clinical, radiological, and neurodevelopmental outcomes between children who receive ketamine vs placebo infusions following traumatic brain injury.1 year

Secondary

MeasureTime frame
To compare the expression of biomarkers of CNS injury between cases and controls.96 hours

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026